We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Minoryx Therapeutics

News List

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong, S.A.R., China and Macau, S.A.R., China prnasia
September 23, 2020
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Roche-backed Minoryx raises €21M to expand CNS R&D fiercebiotech
September 27, 2018
Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.
Minoryx Therapeutics completes phase 1 clinical trial for MIN-102 biospectrumasia
March 23, 2017
MIN-102 was well-tolerated at much higher doses than those required for efficacy
Minoryx Therapeutics receives Orphan Drug Designation for its lead candidate MIN-102 biospectrumasia
February 24, 2017
MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need